Search
Fianlimab
go.drugbank.com/drugs/DB18858InvestigationalFianlimab is under investigation in clinical trial NCT06190951 (A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-pd1 Alone in Adult Participants With Resectable Stage 3 or
Cofirasersen
go.drugbank.com/drugs/DB19037InvestigationalCofirasersen is under investigation in clinical trial NCT04441788 (A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary
Fusafungine
go.drugbank.com/drugs/DB08965ApprovedWithdrawnFusafungine is an antibiotic from Fusarium lateririum, and is used for the treatment of respiratory infections.
Nafithromycin
go.drugbank.com/drugs/DB16246InvestigationalNafithromycin is under investigation in clinical trial NCT02903836 (Phase II Study of Oral Nafithromycin in CABP).
Q-Derp1
go.drugbank.com/drugs/DB05857ExperimentalQ-Derp1 is developed by Cytos Biotechnology as an immunodrug. It is an antigen for the prevention of various major chronic diseases. Derp1 is the dominant allergic protein found in dust mite feces.
Cenacitinib
go.drugbank.com/drugs/DB21735InvestigationalCenacitinib is a small molecule drug. The usage of the INN stem '-citinib' in the name indicates that Cenacitinib is a Janus kinase inhibitor. … Cenacitinib is under investigation in clinical trial NCT05688852 (VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease).
HMI-103
go.drugbank.com/drugs/DB17684InvestigationalHMI-102 is an investigational gene therapy designed to encode the phenylalanine-4-hydroxylase (PAH) gene, mutated in people with phenylketonuria.
OPB-111077
go.drugbank.com/drugs/DB16630InvestigationalOPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation. It has demonstrated promising anticancer activity in preclinical models.
Tiazofurine
go.drugbank.com/drugs/DB13243ExperimentalTiazofurine has potential clinical use in cancer treatment as it is a potential inhibitor of Inosine- 5’-monophosphate (IMP) dehydrogenase [A174991].
RCT1100
go.drugbank.com/drugs/DB18830InvestigationalRCT1100 is an investigational mRNA-based therapeutic that aims to treat primary ciliary dyskinesia caused by pathogenic mutations in DNAI1.[L50788]